Treatment with GLP-1 and combined GIP/GLP-1 medications in MODY: a case series

Competing interests: DTB, MFdF, EAO and BEG receive grant support from the Caswell Diabetes Institute and from the National Institutes of Health (grant U54DK118612-04). EAO and MFdF are funded by the National Institutes of Health (grant R01DK125513). Duality of Interest. DTB is a research investigator for Fractyl Health Laboratories, Sanofi, the Type 1 Diabetes Exchange (T1DX-QI), and Rhythm Pharmaceuticals. MFdF is an advisory board member for PTC Pharmaceuticals and was a scientific presenter in a symposium funded by Amryt Pharmaceuticals. EAO has received grant support from Aegerion Pharmaceuticals (manufacturer of metreleptin), Akcea Therapeutics, Ionis Pharmaceuticals, Gemphire Therapeutics, Novo Nordisk, Rhythm Pharmaceuticals, Fractyl Health Laboratories and GI Dynamics. EAO has served as an advisor and/or a consultant to Aegerion Pharmaceuticals, Akcea Therapeutics, Ionis Pharmaceuticals, and Regeneron. EAO has royalty rights from the use of metreleptin in lipodystrophy. WHH is on data safety and monitoring boards for Merck Sharp & Dohme and Rivus Pharmaceuticals. No other potential conflicts of interest relevant to this article were reported.